Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

被引：0
|
作者：
Carol H. Wysham
Patrick Lefebvre
Dominic Pilon
Mike Ingham
Marie-Hélène Lafeuille
Bruno Emond
Rhiannon Kamstra
Wing Chow
Michael Pfeifer
Mei Sheng Duh
机构：
[1] Rockwood Clinic,
[2] Groupe d’analyse,undefined
[3] Ltée,undefined
[4] Janssen Scientific Affairs,undefined
[5] LLC,undefined
[6] Johnson & Johnson,undefined
[7] Analysis Group,undefined
[8] Inc.,undefined
来源：
BMC Endocrine Disorders | / 17卷
关键词：
Canagliflozin; Type 2 diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; HbA1c; Blood pressure; Weight loss;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Neumiller, Joshua J.
    Campbell, R. Keith
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (18) : 1515 - 1525
  • [42] Effect of dipeptidyl peptidase-4 inhibitors on tumor necrosis factor alpha levels in patients with type 2 diabetes mellitus
    Zhao, Lijia
    Meng, Jie
    Bai, Xueyan
    Zhang, Donglei
    Yang, Xingsheng
    Yang, Yu
    Cai, Gaojun
    Liu, Xin
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2024, 29 (01) : 363
  • [43] Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
    Han, Eugene
    Lee, Minyoung
    Lee, Yong-ho
    Kim, Hye Soon
    Lee, Byung-wan
    Cha, Bong-Soo
    Kang, Eun Seok
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 4113 - 4121
  • [44] Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus
    Forst, Thomas
    Pfuetzner, Andreas
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (01) : 21 - 35
  • [45] Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Jarvis, Courtney I.
    Cabrera, Adriana
    Charron, Derek
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1532 - 1539
  • [46] Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Johnson, Kathryn M. S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (04) : 455 - 463
  • [47] Treatment of Elderly Patients With Type 2 Diabetes Mellitus: A Systematic Review of the Benefits and Risks of Dipeptidyl Peptidase-4 Inhibitors
    Schwartz, Sherwyn L.
    AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2010, 8 (05): : 405 - 418
  • [48] The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus
    Sadidi, Mohammad
    Zare, Ahad
    Nasrollahzadehsabet, Mehrdad
    Dastan, Farzaneh
    Khah, Ali Mosadegh
    Jafari Asheyani, Milad
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2022, 27 (01): : 62
  • [49] Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
    Herman, G. A.
    Stein, P. P.
    Thornberry, N. A.
    Wagner, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 761 - 767
  • [50] Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
    Carolyn F. Deacon
    Nature Reviews Endocrinology, 2020, 16 : 642 - 653
12345